STOCK TITAN

Neurogene, Inc. - NGNE STOCK NEWS

Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.

Neurogene, Inc. (NGNE) is a clinical-stage biotechnology company focused on leveraging gene therapy to treat severe neurological diseases. With headquarters in Seattle, Washington, Neurogene's mission is to transform the lives of patients with complex neurological conditions through innovative genetic solutions. The company utilizes its proprietary EXACT gene regulation technology, which offers precise control over gene expression, enhancing the efficacy and safety of its treatments.

Neurogene's lead product candidate, NL-201, is designed to mimic the therapeutic benefits of cytokines interleukin (IL)-2 and IL-15. This de novo protein aims to treat various types of cancer, including renal cell carcinoma and melanoma. The company is dedicated to developing immunotherapies for cancer, inflammation, and autoimmunity disorders using advanced protein design technology.

Founded in 2003 and initially named Aquinox Pharmaceuticals, Inc., the company rebranded to Neoleukin Therapeutics, Inc. in August 2019, before evolving into the specialized entity it is today, Neurogene, Inc. The company has established significant partnerships and collaborations within the biotech industry, aiming to leverage these relationships to accelerate the development and commercialization of their gene therapy solutions.

Neurogene's financial health is bolstered by a robust pipeline of transformative therapies and a dedicated team of experts. The company continues to innovate and expand its research and development efforts, aiming to bring life-changing therapies to patients who currently have limited treatment options.

For the latest updates on Neurogene, Inc. (NGNE), including financial performance, new research, and other significant developments, visit the News section on StockTitan.

Rhea-AI Summary

Neurogene (NASDAQ: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, announced participation in several upcoming conferences.

At the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, management will present a corporate overview and meet with investors.

On June 18-19, 2024, at the IRSF Rett Syndrome Scientific Meeting, interim safety data from the NGN-401 gene therapy trial for Rett syndrome will be presented by management and Dr. Bernhard Suter.

Additionally, Neurogene will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 21, 2024. Live webcasts of these events will be available on Neurogene’s Investor Relations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary

Neurogene (NASDAQ: NGNE) announced that its NGN-401 gene therapy for Rett syndrome has been chosen by the FDA for the START Pilot Program, aimed at accelerating the development of rare disease therapies. NGN-401 is one of only three programs selected by the CBER division, due to its potential clinical benefits and readiness for clinical development.

This selection allows Neurogene enhanced communication with the FDA to resolve product-specific development issues promptly. Currently, NGN-401 is being evaluated in a Phase 1/2 clinical trial, focusing on safety, tolerability, and preliminary efficacy in female pediatric patients. Interim efficacy data is expected in Q4 2024.

Neurogene recently reported favorable safety data from the first three patients dosed. The START Program aims to provide frequent FDA advice to facilitate the program's development and generate high-quality data for potential future marketing applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
-
Rhea-AI Summary

Neurogene Inc. (Nasdaq: NGNE) reported its first quarter 2024 financial results and highlighted recent corporate updates, focusing on the NGN-401 gene therapy trial for Rett syndrome. The company presented favorable safety data at the ASGCT Annual Meeting, received Australian HREC approval for the trial, and remains on track to provide interim efficacy data in Q4:24. Neurogene maintains a strong balance sheet with cash runway into 2H:26.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
Rhea-AI Summary

Neurogene Inc. presented favorable safety data from the Phase 1/2 trial of NGN-401 Gene Therapy for Rett Syndrome at the ASGCT Annual Meeting. The therapy was well-tolerated by the first three patients dosed, showing no signs of overexpression toxicity. The company remains on track to provide interim efficacy data in the fourth quarter of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
-
Rhea-AI Summary
Neurogene announces the upcoming presentation of safety data from the Phase 1/2 trial of NGN-401 gene therapy for Rett Syndrome at the ASGCT Meeting. The data show that NGN-401 has been well-tolerated with no serious adverse events. The gene therapy candidate aims to deliver a full-length MECP2 gene to key brain areas, addressing the pathophysiology of Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences clinical trial
-
Rhea-AI Summary
Neurogene Inc. announces strong financial results for Q4 2023 and full year, with a focus on expanded Phase 1/2 gene therapy trial for Rett syndrome. The company remains on track to share interim clinical data in Q4 2024. Neurogene's NGN-401 gene therapy shows promise in treating Rett syndrome, with positive safety outcomes. The company's financial position is robust with a cash runway into 2H:26 after a reverse merger and private financing in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
Rhea-AI Summary
Neurogene Inc. (NASDAQ: NGNE) expands Phase 1/2 trial for NGN-401 for Rett syndrome, adding more patients and a high dose cohort. Removal of staggered dosing expected to speed up enrollment. Third patient dosed in Cohort 1. Updates aim to inform future registrational trial design and enhance biodistribution to the brain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.47%
Tags
-
Rhea-AI Summary
Neurogene Inc. (NASDAQ: NGNE) announced its participation in upcoming investor conferences to discuss its genetic medicines for rare neurological diseases. Management will engage in various formats at TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Stifel 2024 Virtual CNS Days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
conferences
-
Rhea-AI Summary
Neurogene Inc. (NASDAQ: NGNE) announced the appointment of Julie Jordan, M.D., as Chief Medical Officer. Dr. Jordan brings over 20 years of industry and clinical expertise in global clinical trials, gene therapy, and central nervous system disorders. She most recently served as Chief Medical Officer of Homology Medicines. Neurogene's CEO, Rachel McMinn, expressed excitement about Dr. Jordan's leadership and experience, emphasizing the potential impact on advancing the company's pipeline of genetic medicines, including NGN-401 for the treatment of Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
management
Rhea-AI Summary
Neurogene Inc. (NGNE) announces DSMB clearance for third pediatric patient in NGN-401 Phase 1/2 clinical trial for Rett syndrome and CTA clearance from UK MHRA, with a strong financial position of $200 million in cash and runway into 2H:26
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
none

FAQ

What is the current stock price of Neurogene (NGNE)?

The current stock price of Neurogene (NGNE) is $24.1 as of December 26, 2024.

What is the market cap of Neurogene (NGNE)?

The market cap of Neurogene (NGNE) is approximately 346.1M.

What does Neurogene, Inc. do?

Neurogene, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for severe neurological diseases.

What is Neurogene's lead product candidate?

Neurogene's lead product candidate is NL-201, a de novo protein designed to mimic the activity of cytokines IL-2 and IL-15 for cancer treatment.

Where is Neurogene, Inc. headquartered?

Neurogene, Inc. is headquartered in Seattle, Washington.

What technology does Neurogene use for its treatments?

Neurogene uses its proprietary EXACT gene regulation technology for precise control over gene expression in its therapy development.

When was Neurogene, Inc. founded?

Neurogene, Inc. was founded in 2003.

What was the former name of Neurogene, Inc.?

The company was formerly known as Aquinox Pharmaceuticals, Inc. before changing its name to Neoleukin Therapeutics, Inc. in 2019.

What types of diseases does Neurogene aim to treat?

Neurogene aims to treat severe neurological diseases, cancer, inflammation, and autoimmunity disorders.

What is the EXACT gene regulation technology?

The EXACT gene regulation technology is a proprietary system developed by Neurogene to offer precise control over gene expression, enhancing the safety and efficacy of gene therapies.

Does Neurogene have any partnerships?

Yes, Neurogene has established significant partnerships and collaborations within the biotech industry to advance its research and development efforts.

How can I stay updated about Neurogene, Inc.?

You can stay updated about Neurogene, Inc. by visiting the News section on StockTitan for the latest financial performance, new research, and other significant developments.

Neurogene, Inc.

Nasdaq:NGNE

NGNE Rankings

NGNE Stock Data

346.12M
13.39M
10.69%
110.72%
7.04%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK